Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
ABBOTT LABORATORIES Senior Vice President Orville Jacob A filed an initial ownership report showing 37,238 common shares held directly. These shares represent a restricted stock unit award with a four-year term, vesting in equal annual installments starting on February 25, 2027, with the ability to have shares withheld for taxes.
The report follows Abbott’s acquisition of Exact Sciences Corporation, where each Exact common share was converted into the right to receive $105.00 in cash. Certain Exact restricted stock units were assumed by Abbott and converted into Abbott restricted stock units based on this merger consideration and Abbott’s 10-day average share price before closing.
Abbott Laboratories has completed its acquisition of Exact Sciences, making Exact a wholly owned subsidiary focused on cancer screening and diagnostics. Each Exact Sciences common share was converted into the right to receive $105.00 in cash at closing. Exact’s last trading day on Nasdaq was March 20, 2026. The deal adds leading products such as Cologuard, Oncotype DX, Oncodetect and Cancerguard, and expands Abbott’s presence in U.S. cancer screening and precision oncology diagnostics, which the company cites as a $60 billion market.
Abbott Laboratories is asking shareholders to vote on five items at its 2026 Annual Meeting, including electing 12 directors, ratifying Ernst & Young as auditors, approving executive pay on an advisory basis, and adopting new 2026 incentive and non‑U.S. employee stock purchase plans.
The proxy highlights strong long-term performance, with 2025 total shareholder return of 13% versus a 7% peer median, and three‑ and five‑year TSR of 21% and 25%, both above peers. Abbott returned $5 billion to shareholders in 2025 and raised its dividend by 6.8%, its 54th consecutive annual increase.
The board stresses governance, noting that 11 of 12 nominees are independent, all directors are elected annually by majority vote, and committees are fully independent. The company also emphasizes sustainability and human capital goals, including a 2030 plan to expand access to healthcare, cut emissions, and build a diverse, future-ready workforce.
Abbott Laboratories completed a major debt financing, issuing $20 billion of senior notes in multiple tranches maturing between 2029 and 2066, including fixed-rate coupons from 3.700% to 5.600% and a floating-rate 2029 series.
Abbott plans to use the net proceeds, along with cash and possible additional borrowings, to fund the acquisition of Exact Sciences Corporation, repay Exact Sciences’ debt, cover related fees and expenses, and for general corporate purposes such as debt repayment. If the Exact Sciences acquisition is not completed by a deadline tied to the merger agreement’s End Date, or Abbott abandons the deal, Abbott must redeem all outstanding notes at 101% of principal plus accrued interest under a special mandatory redemption feature.
Abbott Laboratories senior vice president Eric Shroff reported two stock transactions involving Abbott common shares. On March 2, 2026, he completed an open-market sale of 709 shares at a price of $115.58 per share, leaving him with 39,164 directly held shares afterward.
On February 27, 2026, he disposed of 1,384 shares at $116.26 per share to cover tax withholding obligations, a non-market transaction typically linked to equity compensation. Both holdings are reported as direct ownership of common shares without par value.
Abbott Laboratories executive Christopher J. Scoggins reported a tax-related share disposition. On February 27, 2026, he had 4,997 common shares withheld at $116.26 per share in a tax-withholding disposition, classified under code F as payment of tax liability by delivering securities.
After this non-open-market transaction, Scoggins’ directly owned holdings in Abbott Laboratories common shares were reported as 77,126 shares.
Abbott Laboratories executive Daniel Gesua Sive Salvadori, EVP and Group President, reported two share transactions. On March 2, 2026, he executed an open-market sale of 885 common shares at $115.58 per share. On February 27, 2026, he disposed of 6,615 shares at $116.26 per share to satisfy tax-withholding obligations. Following these transactions, he directly holds 146,377 Abbott common shares.
Abbott Laboratories executive Louis H. Morrone reported selling 1,144 common shares in an open‑market transaction at $115.58 per share on March 2, 2026. After this sale, his directly held stake was 76,843 common shares.
On February 27, 2026, 4,040 common shares were disposed of at $116.26 per share to cover tax withholding obligations rather than as an open‑market sale. The filing also notes 12 common shares held indirectly through a Profit Sharing Trust as of February 27, 2026.
ABBOTT LABORATORIES Executive Vice President Mary K. Moreland reported insider share transactions. On March 2, 2026, she completed an open-market sale of 613 common shares at $115.58 per share. On February 27, 2026, 4,630 common shares were disposed of at $116.26 per share to cover tax liabilities by delivering shares.
After these transactions, her directly held common shares totaled 104,291. In addition, 11,845 common shares were held indirectly through a Profit Sharing Trust, with that trust balance reported as of February 27, 2026.